title: ÐÐ¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÑÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð¿ÑÐ¾Ñ Ð¾Ð´ÑÑÐ¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½ÑÑ ÑÐµÑÐ°Ð¿Ð¸Ñ Ñ 225Ac-PSMA, Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¸Ð·Ð¾Ð±ÑÐ°Ð¶ÐµÐ½Ð¸Ð¹ Ð¿ÑÐµÐ´Ð²Ð°ÑÐ¸ÑÐµÐ»ÑÐ½ÑÑ ÐÐ­Ð¢-ÑÐºÐ°Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ð¹
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Determination of absorbed doses in pathological tumors and critical organs in patients undergoing radionuclide therapy with 225Ac PSMA based on pre-PET scan images
Creators: name: ÐÐ°Ð²ÑÐµÑÐ¾Ð², ÐÐ¼Ð¸ÑÑÐ¸Ð¹
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÐºÐ°
ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð°Ñ ÑÐµÑÐ°Ð¿Ð¸Ñ
ÑÐµÑÐ°Ð½Ð¾ÑÑÐ¸ÐºÐ°
ÑÐ°Ð´Ð¸Ð¾ÑÐ°ÑÐ¼Ð°ÑÐµÐ²ÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð¿ÑÐµÐ¿Ð°ÑÐ°Ñ
225Ac
68Ga
Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ
ÐÐ¡ÐÐ
radionuclide diagnostics
radionuclide therapy
theranostics
radiopharmaceutical
absorbed dose
PSMA

description: ÐÐ»Ñ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾Ð³Ð¾ Ð¸ Ð±ÐµÐ·Ð¾Ð¿Ð°ÑÐ½Ð¾Ð³Ð¾ Ð»ÐµÑÐµÐ½Ð¸Ñ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ 225Ac-PSMA Ð²Ð¾Ð·Ð¼Ð¾Ð¶Ð½Ð¾ Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¿Ð»Ð°Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ, Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð½Ð° Ð¾ÑÐµÐ½ÐºÐµ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ Ð Ð¤ÐÐ Ð² Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ. ÐÑÐ½Ð¾Ð²Ð½Ð°Ñ ÑÐµÐ»Ñ Ð¼Ð°Ð³Ð¸ÑÑÐµÑÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ â Ð´Ð¾Ð·Ð¸Ð¼ÐµÑÑÐ¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ñ 225Ac-PSMA Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸Ð¸ ÐÐ­Ð¢/ÐÐ¢ Ñ 68Ga-PSMA. Ð ÑÐ°Ð±Ð¾ÑÐµ Ð±ÑÐ» Ð¿ÑÐ¾Ð¸Ð·Ð²ÐµÐ´ÐµÐ½ ÑÐ°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð²ÑÐ±ÑÐ°Ð½Ð½ÑÑ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¿ÑÐ¾ÑÐ¾Ð´ÑÑÐµÐ³Ð¾ Ð ÐÐ¢ Ñ 225Ac-PSMA Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ Ð¸Ð·Ð¾Ð±ÑÐ°Ð¶ÐµÐ½Ð¸Ð¹ Ð¿ÑÐµÐ´Ð²Ð°ÑÐ¸ÑÐµÐ»ÑÐ½ÑÑ ÐÐ­Ð¢-ÐÐ¢ ÑÐºÐ°Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ð¹ Ñ 68Ga-PSMA. ÐÐ·Ð¾Ð±ÑÐ°Ð¶ÐµÐ½Ð¸Ñ Ð±ÑÐ»Ð¸ Ð¿Ð¾Ð»ÑÑÐµÐ½Ñ Ð½Ð° Ð°Ð¿Ð¿Ð°ÑÐ°ÑÐµ Siemens Biograph mCT. ÐÑÐ»Ð° Ð¿ÑÐ¾Ð¸Ð·Ð²ÐµÐ´ÐµÐ½Ð° Ð¸Ñ ÑÐµÐ³Ð¼ÐµÐ½ÑÐ°ÑÐ¸Ñ Ð² Ð¿ÑÐ¾Ð³ÑÐ°Ð¼Ð¼Ðµ VIDAR DICOM Viewer Ð¸ ÑÐ°ÑÑÐµÑ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ 68Ga-PSMA Ð² ÑÐµÑÑÐ¸ Ð²ÑÐ±ÑÐ°Ð½Ð½ÑÑ Ð¾ÑÐ°Ð³Ð°Ñ Ð¸ ÐºÑÐ¸ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¾ÑÐ³Ð°Ð½Ð°Ñ. ÐÐ¾ÑÐ»Ðµ ÑÐµÐ³Ð¾ Ð¿ÑÐ¾Ð¸Ð·Ð²ÐµÐ´ÐµÐ½Ð¾ Ð¿ÑÐµÐ¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð´Ð°Ð½Ð½ÑÑ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸Ñ Ð´Ð»Ñ 225Ac-PSMA Ð¸ ÑÐ°ÑÑÐµÑ Ð¿Ð¾Ð³Ð»Ð¾ÑÑÐ½Ð½ÑÑ Ð´Ð¾Ð· Ñ ÑÑÐµÑÐ¾Ð¼ Ð´Ð¾ÑÐµÑÐ½Ð¸Ñ ÑÐ°Ð´Ð¸Ð¾Ð½ÑÐºÐ»Ð¸Ð´Ð¾Ð². ÐÐ¾ Ð²ÑÐµÑ Ð¾ÑÐ°Ð³Ð°Ñ Ð¿Ð¾ÑÐ°Ð¶ÐµÐ½Ð¸Ñ Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð¾ÑÑ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ Ð·Ð°ÑÐ²Ð°ÑÐ° Ð´Ð¸Ð°Ð³Ð½Ð¾ÑÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð Ð¤ÐÐ Ð¿Ð°ÑÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ð¼Ð¸ Ð¾ÑÐ°Ð³Ð°Ð¼Ð¸ Ð¸ ÑÐ¼ÐµÐ½ÑÑÐµÐ½Ð¸Ðµ Ð¸Ñ ÑÐ°Ð·Ð¼ÐµÑÐ¾Ð², ÑÑÐ¾ ÑÐºÐ°Ð·ÑÐ²Ð°ÐµÑ Ð½Ð° ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑ Ð»ÐµÑÐµÐ½Ð¸Ñ. ÐÑÐ»Ð¸ ÑÐ°ÑÑÐ¼Ð°ÑÑÐ¸Ð²Ð°ÑÑ ÐºÐ¾ÑÑÐ½ÑÐµ Ð¾ÑÐ°Ð³Ð¸, ÑÐ¾ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÐµ Ð´Ð¾Ð·Ñ ÑÐ¼ÐµÐ½ÑÑÐ°Ð»Ð¸ÑÑ Ð¿Ð¾ÑÐ»Ðµ Ð²ÑÐ¾ÑÐ¾Ð³Ð¾ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ 225Ac-PSMA. Ð ÑÐ¾ Ð¶Ðµ Ð²ÑÐµÐ¼Ñ ÑÐ¼ÐµÐ½ÑÑÐµÐ½Ð¸Ðµ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½ÑÑ Ð´Ð¾Ð· Ð² Ð¼ÑÐ³ÐºÐ¸Ñ ÑÐºÐ°Ð½ÑÑ Ð¿ÑÐ¾Ð¸ÑÑÐ¾Ð´Ð¸Ð»Ð¾ Ð¼ÐµÐ½ÐµÐµ Ð¸Ð½ÑÐµÐ½ÑÐ¸Ð²Ð½Ð¾, Ð´Ð¾ÑÑÐ¸Ð³Ð°Ñ Ð¼Ð°ÐºÑÐ¸Ð¼Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ ÑÑÐ¾Ð²Ð½Ñ Ð¿Ð¾ÑÐ»Ðµ ÑÑÐµÑÑÐµÐ³Ð¾ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ. ÐÐ¾ÑÐ»Ðµ Ð¾Ð´Ð½Ð¾Ð³Ð¾ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ñ, Ð¼Ð°ÐºÑÐ¸Ð¼Ð°Ð»ÑÐ½Ð°Ñ Ð¿Ð¾Ð³Ð»Ð¾ÑÐµÐ½Ð½Ð°Ñ Ð´Ð¾Ð·Ð° Ð±ÑÐ»Ð° Ð·Ð°ÑÐµÐ³Ð¸ÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð° Ð² ÐºÐ¾ÑÑÐ½Ð¾Ð¼ Ð¾ÑÐ°Ð³Ðµ 1 Ð¸ ÑÐ¾ÑÑÐ°Ð²Ð¸Ð»Ð° 7,6 ÐÑ, Ð¿ÑÐ¸ Ð²Ð²ÐµÐ´ÐµÐ½Ð¸Ð¸ 1 ÐÐÐº Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ 225Ac-PSMA.
description: For effective and safe treatment with 225Ac-PSMA, it is possible to carry out individual dosimetric planning based on the assessment of radiopharmaceutical accumulation in pathological tumors and critical organs. The main object of the masters work is the dosimetry of radionuclide therapy with 225Ac-PSMA based on PET / CT with 68Ga-PSMA. In this work, the absorbed doses were calculated in selected tumors and critical organs in a patient undergoing radionuclide therapy with 225Ac-PSMA based on images of preliminary PET-CT scans with 68Ga-PSMA. The images were obtained using a Siemens Biograph mCT machine. They were segmented in the VIDAR DICOM Viewer program and the accumulation of 68Ga-PSMA in six selected tumors and critical organs was calculated. After that, the accumulation data for 225Ac-PSMA were converted and the absorbed doses were calculated the daughter radionuclides. In all lesions, there was a decrease in the capture of diagnostic radiopharmaceuticals by pathological tumors and a decrease in their size, which indicates the effectiveness of the treatment. If we consider the bone tumors, then the absorbed doses decreased after the second injection of 225Ac-PSMA. At the same time, the decrease in absorbed doses in soft tissues was less intense, reaching a maximum level after the third injection. After a single injection, the maximum absorbed dose was recorded in bone tumor 1 and amounted to 7.6 Gy, with the introduction of 1 MBq of 225Ac-PSMA activity.